INTEGRATIVE AND BIOCHEMICAL PARAMETERS IN RATS IN THE SIMULATION OF DOXORUBICIN CHRONIC HEART FAILURE AND DURING THE USE OF Β-ADRENERGIC BLOCKERS
-
Published:2023-01-31
Issue:1
Volume:47
Page:21-21
-
ISSN:1015-3918
-
Container-title:Ankara Universitesi Eczacilik Fakultesi Dergisi
-
language:en
-
Short-container-title:Ankara Ecz. Fak. Derg.
Author:
BELENİCHEV Igor1, BAK Pavlo1, POPAZOVA Olena2, RYZHENKO Victor1, BUKHTİYAROVA Nina1, PUZYRENKO Andrii3
Affiliation:
1. Zaporizhzhia State Medical University 2. Zaporizhzhia State Medical Universit 3. College of Wisconsin
Abstract
β-adrenergic blockers have been actively used in the treatment of heart failure, which relieve excessive sympathetic stimulation of the myocardium, reduce calcium overload of cardiomyocytes, reduce the heart's oxygen demand, inhibit lipid peroxidation and stabilize cell membranes, have an antiarrhythmic effect. The aim: to compare efficiency of various drugs with new potential "Hypertril" in the conditions of modeling doxorubicin chronic heart failure (CHF) to improve parameters. Objective: CHF was modeled on 85 white outbred rats weighing 190–220g by administering doxorubicin at a cumulative dose of 15 mg/kg. Material and metods: Nebivalol, Carvedilol, Bisoprolol, Metoprolol and Hypertril were administered intragastrically once a day in the form of a suspension of 1% starch mucus for 30 days after a 14-day administration of doxorubicin. To determine damage, we used the solid-phase immunosorbent sandwich ELISA method, enzyme immunoassay and the immunoturbodimetric method. Result and discussion: Administration of Hypertril to rats with CHF led to a decrease in the blood of the main molecular markers of CHF to the values of intact animals, which indicated its significant cardioprotective effect in comparison with other drugs. Hypertril reduces manifestations of mitochondrial dysfunction, protects the myocardium and positively affects the morphological and functional parameters of cardiomyocytes, inhibits apoptosis
Publisher
Ankara Universitesi Eczacilik Fakultesi Dergisi
Subject
Pharmaceutical Science,Pharmacology
Reference29 articles.
1. • Bak, P.G., Belenichev, I.F., Kucherenko, L.I., Abramov, A.V., Khromylоva, O.V. (2021). Morpho-functional indicators changes of rats’ myocardium in experimental doxorubicin-induced chronic heart failure and its pharmacological modulation with new 4-amino-1,2,4-triazole derivative. Pharmacia; 68(4): 919–925. https://doi.org/10.3897/pharmacia.68.e75298 2. • Belenichev, I., Gorbachova, S., Pavlov, S., Bukhtiyarova, N., Puzyrenko, A., Brek, O. (2021a). Neurochemical status of nitric oxide in the settings of the norm, ishemic event of central nervous system, and pharmacological intervention. Georgian Medical New, 315: 169–176. 3. • Belenichev, I.F., Bak, P.G., Abramov, A.V., Kucherenko, L.I., Bukhtiyarova, N.V., Rizhenko, V.P. (2021b). ECG analysis in the simulation of chronic heart failure in rats and course administration of a new potential drug “Hypertril”. Pharmacology and toxicology, 15(1): 20–30. 4. • Bien, S., Riad, A., Ritter, C.A., Gratz, M., Olshausen, F., Westermann, D., Kroemer, H.K. (2007). The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer research;. 67(21):10428–10435. https://doi.org/10.1158/0008-5472.CAN-07-1344 5. • Bozkurt, B., Coats, A.J., Tsutsui, H., Abdelhamid, C.M., Adamopoulos, S., Albert, N., Zieroth, S. et al. (2021). Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: European Journal of Heart Failure, 23(3): 352–380. PMID: 33605000. https://doi.org/10.1002/ejhf.2115
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|